All In Biotech

BLA 761390 · Galderma Labs Lp

Nemluvio

Nemolizumab-Ilto · Injection · Interleukin-31 Receptor alpha Antagonist

NovelBreakthrough therapyPriority review

CDER novel approval, Aug 12, 2024: To treat prurigo nodularis

Last checked: Nov 20, 2026Latest source record: Jun 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Aug 12, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

27

11 Phase 3, 6 recruiting

FAERS reports

15,930

1,068 serious, 156 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 26, 2025.

NEMLUVIO is an interleukin-31 receptor antagonist indicated for: Prurigo Nodularis The treatment of adults with prurigo nodularis. ( 1.1 ) Atopic Dermatitis The treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. ( 1.2 ) 1.1 Prurigo Nodularis NEMLUVIO is indicated for the treatment of adults with prurigo nodularis. 1.2 Atopic Dermatitis NEMLUVIO is indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.

Mechanism: Nemolizumab-ilto is a humanized IgG2 monoclonal antibody that inhibits IL-31 signaling by binding selectively to IL-31 RA. IL-31 is a naturally occurring cytokine that is involved in pruritus, inflammation, epidermal dysregulation, and fibrosis. Nemolizumab-ilto inhibited IL-31-induced responses including the release of proinflammatory cytokines and chemokines.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 12, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
  • NEMLUVIO · NEMOLIZUMAB-ILTO 30MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nemolizumab" as an intervention, any sponsor and status, largest first.

All 27 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue5,792
  • device malfunction2,529
  • pruritus1,581
  • inappropriate schedule of product administration1,578
  • incorrect dose administered1,544
  • rash1,056
  • drug ineffective947
  • device use error658
  • dermatitis atopic556
  • headache505
  • eczema420
  • device leakage403

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20202
20224
20236
2024161
20257,279
20268,478

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nemluvio (Nemolizumab-Ilto)

2024 spending

$13.7M

Beneficiaries

967

2,005 claims

Per beneficiary

$14,159

$4,193.38 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$13,691,381

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 50 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.